Miranda A. Lewis

Miranda A. Lewis

Auto-generated profile, based on publicly available information

Miranda A. Lewis

Department of Molecular Virology and Microbiology, Baylor College of Medicine , Houston, Texas, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
MLMiranda A. Lewis
Miranda A. Lewis
NCNicolás W. Cortés-Penfield
Nicolás W. Cortés-Penfield
KEKhalil Ettayebi
Khalil Ettayebi
KPKetki Patil
Ketki Patil
GKGurpreet Kaur
Gurpreet Kaur
MEMary K. Estes
Mary K. Estes
Human noroviruses (HuNoVs) are the leading cause of acute gastroenteritis. In immunocompetent hosts, symptoms usually resolve within 3 days; however, in immunocompromised persons, HuNoV infection can become persistent, debilitating, and sometimes life-threatening. There are no licensed therapeutics for HuNoV due to a near half-century delay in its cultivation. Treatment for chronic HuNoV infection in immunosuppressed patients anecdotally includes nitazoxanide, a broad-spectrum antimicrobial licensed for treatment of parasite-induced gastroenteritis. Despite its off-label use for chronic HuNoV infection, nitazoxanide has not been clearly demonstrated to be an effective treatment. In this study, we standardized a pipeline for antiviral testing using multiple human small intestinal enteroid lines representing different intestinal segments and evaluated whether nitazoxanide inhibits replication of five HuNoV strains in vitro . Nitazoxanide did not exhibit high selective antiviral activity against any HuNoV strain tested, indicating it is not an effective antiviral for HuNoV infection. Human intestinal enteroids are further demonstrated as a model to serve as a preclinical platform to test antivirals against HuNoVs to treat gastrointestinal disease. Abstr